Verseon anti-coagulant drugs – new data highlights low bleed risk

Verseon presents further trial data on the low bleeding risk of its family of preclinical anti-coagulant drugs at BioEurope conference

Further evidence on the low bleeding profile of Verseon’s novel family of anti-coagulants was presented at the BioEurope conference in Stockholm, Sweden. The new data reinforces the promise of Verseon’s novel, highly selective direct thrombin inhibitors (DTIs) as a potential treatment for venous thrombotic disorders while maintaining a lower bleeding risk than current drugs.

The latest preclinical trial results, based on a stasis-induced venous thrombosis model, adds to the list of successful studies performed by the company and broadens the therapeutic potential of Verseon’s DTIs to a wide range of thrombotic disorders, including stroke prevention for atrial fibrillation patients, deep vein thrombosis, pulmonary embolism, and acute coronary syndrome.